Pharmaceutical giant Merck said it plans to acquire privately-held OncoImmune for $425 million in cash, gaining rights to an under-the-radar drug that’s shown striking results in hospitalized patients with Covid-19. Dr. Yang Liu, founder, CEO and chief scientific officer of Oncolmumune, joins “Squawk Box” to discuss the drug as well as the reason for the acquisition. For access to live and exclusive video from CNBC subscribe to CNBC PRO:
» Subscribe to CNBC TV:
» Subscribe to CNBC:
» Subscribe to CNBC Classic:
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:
Connect with CNBC News Online
Get the latest news:
Follow CNBC on LinkedIn:
Follow CNBC News on Facebook:
Follow CNBC News on Twitter:
Follow CNBC News on Instagram:
#CNBC
#CNBCTV
